drugset / Trial / NCT04034641
Effect of Probiotics on Helicobacter Pylori Eradication
Phase 4
Unknown
238 enrolled
Hangzhou Grand Biologic Pharmaceutical, Inc.
Nanjing First Hospital, Nanjing Medical University · collabRenmin Hospital of Wuhan University · collabThe First Affiliated Hospital of Nanchang University · collabThe First Affiliated Hospital of Shanxi Medical University · collabThe First Affiliated Hospital of Zhengzhou University · collabThe First People's Hospital of Yunnan · collabXi'an Central Hospital · collabZhejiang Provincial Hospital of TCM · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple eradication therapy and its influence on gastrointestinal flora.
Timeline
- Start
- 2019-06-17
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifidobacterium quadruple live bacteria tablets | Unknown | — | — |
| Background | Amoxicillin | Other / unclassified | — | — |
| Background | Bismuth Potassium Citrate | Unknown | — | — |
| Background | Esomeprazole | Small molecule | — | — |
| Background | Furazolidone | Small molecule | — | — |